Prostate-specific membrane antigen (PSMA), a type II membrane protein, has been found to be upregulated and strongly expressed on prostate tumor cells and as a consequence, it has attracted significant attention not only as a tumor marker for disease progression but also as both an imaging and therapeutic target for prostate cancer (11). The gene discussed is FOLH1; the disease is prostate neoplasm.